No CrossRef data available.
Article contents
Pharmaceutical Marketing Practices: Pharmaceutical Companies Facing Competition from Generic Drug Manufacturers May Face Increased Scrutiny for Anticompetitive Marketing Practices—In re Warfarin Sodium Antitrust Litig.
Published online by Cambridge University Press: 06 January 2021
Abstract
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Select Recent Court Decisions
- Information
- Copyright
- Copyright © American Society of Law, Medicine and Ethics and Boston University 2005
References
1 391 F.3d 516 (3d Cir. 2004).
2 Id.
3 Id. at 521. More than two million Americans take warfarin sodium to treat blood-clot disorders. Id. at 523. Although DuPont's patent expired in 1962, DuPont has continued to be the dominant manufacturer and supplier of warfarin sodium under the Coumadin brand name. Id. In 1998 and 1999, DuPont recorded sales of warfarin sodium reaching approximately $550 million and $464 million. Id.
4 Id. at 521.
5 Id. at 522.
6 Id. at 522-23.
7 Id. at 523.
8 Id.
9 Id. The publicity campaign emphasized Barr's decision to make a cheaper product for purely monetary reasons and cited DuPont's concerns with patient safety. See 3D Cir. Affirms DuPont's $44.5 Million Coumadin Settlement, 12 NO. 9 Andrews Health L. Litig. Rep. 11, 11 (2005)Google Scholar.
10 In re Warfarin Sodium Antitrust Litig., 391 F.3d at 523.
11 Id.
12 Id.
13 Id.
14 Id.
15 Id. at 524.
16 Id. at 525.
17 Id.
18 Id.
19 Id. at 527.
20 See 3D Cir. Affirms DuPont's $44.5 Million Coumadin Settlement, supra note 9.
21 In re Warfarin Sodium Antitrust Litig., 391 F.3d at 528.
22 Id. at 529.
23 Id. at 528 (quoting Amchem Prods., Inc. v. Windsor, 521 U.S. 591, 625 (1997)).
24 Id. at 530 (discussing rulings in In re Lorazepam & Clorazepate Antitrust Litig., 205 F.R.D. 369 (D.D.C. 2002), and In re Sythroid Mktg. Litig., 188 F.R.D. 295 (N.D. Ill. 1999)).